Project Grant R44AI077225

The National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), awarded a $3,157,784 Project Grant to Synthis Therapeutics, Inc. to conduct in vivo efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) analysis of SYN101, a first-in-class immune cell-targeted TGFβ therapy for cancer patients. The goals of the 22-month project are to: 1) test the efficacy of SYN101 in humanized mouse tumor models and define the comprehensive immune response, and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Chapman University will support the development of small molecule selective inhibitors of neuronal nitric oxide synthase (nNOS) for the treatment of melanoma. The key products and services to be delivered under this $610,415 award, which runs from Jun 2025 to May 2030, include: Designing and synthesizing novel nNOS inhibitors with improved potency, selectivity, and pharmacological properties....

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $113,203 to the University of Chicago to investigate the immunomodulatory effects of a dietary compound called Sumiki's Acid (SKA) on natural killer (NK) cells for cancer immunoprevention. The research aims to determine SKA's potential as a cancer-preventive agent, elucidate its underlying molecular mechanisms, and explore medicinal chemistry and bioengineering approaches to...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $677,176 to The Research Foundation For The State University Of New York (RF SUNY) to advance the development of interstitial chemophototherapy (I-CPT) as a novel treatment approach for locally advanced pancreatic cancer (PACA). The key products and services to be delivered under this 4-year award include: Defining optimal I-CPT light dosimetry for treating large PACA tumors...

This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), provides $1,022,522 to Isoprene Pharmaceuticals Inc. to develop their lead compound VNPP433-3B as a novel oral therapeutic for treating both primary and metastatic prostate cancer. The key objectives are to: 1) Synthesize 500g of non-GMP VNPP433-3B for preclinical studies, 2) Conduct additional pharmacology testing of VNPP433-3B using in vitro and in vivo prostate...

This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), is providing $572,254 over a 3-year period starting February 1, 2025 to identify the first selective inhibitors of PLC𝜸1 and PLC𝜸2. The research aims to screen 200,000 compounds to discover small molecule inhibitors of these two phospholipase C gamma enzymes, which have been implicated in driving oncogenesis. The project will employ high-throughput screening...

This $662,682 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at the University of California, San Diego (UCSD) to develop new combination therapies for treating gastrointestinal stromal tumors (GIST). The research aims to validate the use of voltage-gated potassium channels, specifically the KVβ1.1 protein, as a novel therapeutic target to eliminate both tyrosine kinase inhibitor-sensitive and resistant...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...

The Department of Defense's Defense Health Agency awarded a $1,194,425 Project Grant to The Wistar Institute of Anatomy and Biology to support a 3-year research project titled "DEVELOPING RATIONAL APPROACHES FOR ACRAL MELANOMA" under the Military Medical Research and Development program (CFDA 12.420). The grant will fund basic, translational, and clinical research aimed at developing new treatments and advancing scientific understanding of acral melanoma, a rare form of skin cancer. As...

This SBIR Phase I grant, awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), provides $400,000 to Canget Biotekpharma LLC to perform critical pre-clinical studies and regulatory filings to enable first-in-human clinical trials of their novel cancer drug candidate FL118 for advanced pancreatic cancer. Specifically, the project aims to: (1) conduct non-GLP and GLP toxicology and toxicokinetic studies of the clinically compatible FL118 formulation; and (2) author and...